Since then, supply has returned thanks to Lilly's investments in manufacturing and a move to also offer Zepbound, previously ...

Eli Lilly holds the lead position in the weight management market right now. But Viking Therapeutics is working on a ...

Viking is developing VK2735, its dual GIP/GLP-1 receptor agonist, in injectable form -- like current marketed weight ...

VKTX is likely to have headed into Q3 earnings with no product revenue, pipeline updates in focus and widening loss forecasts testing investor patience.

Viking Therapeutics shows promise with their VK2735 drug demonstrating significant weight loss in Phase 2 trials. Despite strong data, Viking faces intense competition and strategic challenges in a ...

Pfizer has agreed to acquire Metsera, a company specializing in weight-loss medications, for $47.50 per share in cash, along ...

Viking offers asymmetric upside in GLP-1 drugs with positive trial data, strong cash, and buyout potential despite biotech ...

River cruise operator Viking reported first-quarter results on Wednesday morning. The stock sank on the news. Viking's revenue rose 14% -- less than traditional cruise line companies -- but there are ...

Explore the exciting world of Viking Holdings (NYSE: VIK) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and ...

CINCINNATI, Aug. 5, 2025 /PRNewswire/ -- Viking Partners, a private real estate investment firm, closed on a $50.4 million acquisition of a 409,000-square-foot portfolio of small-bay industrial assets ...

Viking’s newly announced 2027-28 deployment includes six ships operating winter itineraries in Europe. Nearly half of the ...